Objectives: To describe cidofovir pharmacokinetics and assess the link between concentration and safety/efficacy in children.
Introduction
Adenovirus and cytomegalovirus infections are major causes of morbidity in immunocompromised patients (e.g. pneumonia, encephalitis, ileitis, colitis, hepatitis and multi-organ failure) and can lead to a mortality risk of up to 60%. 1 Cidofovir is an inhibitor of the viral DNA polymerase, with broad in vitro efficacy against many viruses, including cytomegalovirus and many adenovirus serotypes. 2 However, its government approval is limited in France to the treatment of cytomegalovirus retinitis in HIV-infected adults; European Conference on Infections in Leukaemia guidelines recommend its use as a first-line paediatric drug for the treatment of adenovirus-related disease and/or infections and as part of second-line antiviral regimens to treat cytomegalovirus infections after allogeneic HSCT. 3 Cidofovir has been used in these indications for many years, despite the absence of randomized controlled trials demonstrating its efficacy and the absence of consensus on dosage or scheduling of this drug in these indications. Moreover, the frequency and severity of cidofovirrelated adverse events, particularly nephrotoxicity, in immunocompromised children remain unclear.
Cidofovir is phosphorylated to its active form by intracellular kinases. After administration intravenously, cidofovir is predominantly eliminated by renal excretion via glomerular filtration and active tubular secretion. Between 80% and 100% of the dose is excreted unchanged in the urine within 24 h. The terminal elimination t1 =2 of cidofovir in plasma is short ($2 h). However, the t1 =2 of intracellular phosphorylated cidofovir is longer (17-65 h). 4, 5 The pharmacokinetics of cidofovir in children have only been investigated in one previous study 6 and no model of population pharmacokinetics has been reported to date in this population. Population-based modelling, in contrast with conventional kinetic studies, allows concentrations to be analysed simultaneously within a cohort. It enables a direct estimate (single-step process) of the typical pharmacokinetics parameters (fixed effects) and their variability (random effects) for the observed concentrations. It also detects the covariates that can explain inter-individual variability of the pharmacokinetic parameters. From this model, exposure/efficacy and exposure/toxicity relationships can be studied.
As far as we are aware, our study is the first to establish a model of population pharmacokinetics of cidofovir in immunocompromised children in order to guide cidofovir use in paediatric severe adenovirus and cytomegalovirus infections.
Patients and methods

Ethics
This research was conducted in accordance with the Declaration of Helsinki and national and institutional standards. Parents/guardians provided informed consent for the anonymous use of their children's clinical and biological data for biomedical research at the time of data collection.
Patients and data collection
A retrospective observational study was conducted on immunocompromised children admitted to the paediatric Immunology-Haematology unit of Necker Hospital (Paris, France) who were receiving cidofovir for adenovirus and/or cytomegalovirus infections between 2014 and 2016. Plasma samples were collected within the context of routine drug monitoring, which was performed to look for potential major underexposure or overexposure to cidofovir. Because of the absence of such results, and the absence of consensus on therapeutic drug monitoring of this drug in paediatrics, no dose adjustment was performed in the children. Collection of samples was proposed at 1, 3 and 6 h after drug intake. For each patient, we retrospectively reviewed the demographic, clinical, therapeutic and routine biological data (including cytomegalovirus viraemia, adenovirus viral load in blood and stool, whole-blood count, lymphocyte T count, creatininaemia, kalaemia, calcaemia, phosphoraemia, glycosuria and b2-microglobulinuria).
Weekly monitoring of adenovirus PCR and cytomegalovirus PCR in whole blood was performed in HSCT recipients with at least one risk factor for lifethreatening viral infection [T cell depletion, unrelated donor, cord blood transplantation, grade III or IV graft-versus-host disease (GVHD) and severe lymphopenia], as recommended by the current European guidelines 2011.
3 Similar weekly virological monitoring was performed in our unit in children with severe inherited immune deficiencies that confer high susceptibility to severe viral infections. Adenovirus and cytomegalovirus viral loads in whole blood, stools or nasopharyngeal samples were measured with the CMV R-GENE V R kit (bioMérieux, Marcy l'Étoile, France) and the ADENOVIRUS R-GENE V R kit (bioMérieux), respectively.
Cidofovir administration and plasma drug determination
Patients received intravenous cidofovir (5 mg/kg of bodyweight) as 1 h infusions at day 1, day 8 and then every 2 weeks (if continued). In order to decrease the risk of nephrotoxicity, children received concomitantly (i) oral probenecid (2 g/1.73 m 2 , given 3 h prior to the cidofovir infusion, and two additional 1 g/1.73 m 2 doses at 2 h and 8 h after the infusion, respectively); (ii) intravenous prehydration (normal saline infusion of 1 L/1.73 m 2 /h prior to cidofovir infusion); and (iii) intravenous posthydration (normal saline infusion of 1 L/1.73 m 2 over 3 h after cidofovir infusion).
Blood samples were collected on multiple occasions (usually between one and six times) at various times post-dose ranging from 1 to 13 h after the end of the infusion. Mostly, three samples per occasion were obtained at 1, 3 and 6 h after drug intake. Blood samples were drawn at least 1 week after treatment initiation and during the treatment. The plasma cidofovir concentrations were determined using a validated HPLC method with fluorescence detection, as previously reported by Momper et al. 7 The linearity of the calibration curve of our method was evaluated over the range of 0.1-10 mg/L with a good correlation coefficient (r 2 "0.9985). The lower limit of quantification was set at 0.1 mg/L. The precision and accuracy values ranged from 5.6% to 9.7% and 0.5% to 6.4%, respectively.
Population pharmacokinetic analysis
The population pharmacokinetics analysis was performed using a nonlinear mixed-effect modelling approach with NOMMEM software version VII. 8 One-and two-compartment models were investigated as structural models to describe cidofovir pharmacokinetics using the 'first-order conditional estimation (FOCE) with interaction' method. Several error models (additive, proportional and combined) were tested to describe the residual variability. The inter-individual variability and inter-occasion variability were assumed to be log-normally distributed. Moreover, weight-based allometric scaling was tested to standardize the pharmacokinetics parameters. 9 For the CL parameter, the allometric model was:
in which CL i is clearance in the ith individual with body weight WT i and h CL is the typical value of the clearance in a standardized adult with a body weight of 70 kg. The minimal value of the objective function was used to discriminate between hierarchical models (P " 0.05, v 2 distribution, 1 degree of freedom).
Covariate model
Firstly, the association between available physiological covariates at baseline (sex, age, body weight, creatinine clearance and probenecid dose) and pharmacokinetics parameters were investigated graphically. The empirical Bayes estimates of the individuals' pharmacokinetics parameters obtained from the base model were plotted against each covariate. They were then tested using a stepwise covariate model approach. The relationship between continuous covariates and pharmacokinetics parameters was modelled using linear, exponential and power functions with the covariates centred at their median values. The influence of categorical covariates was tested according to the equation:
where h 1 represents the typical value of pharmacokinetics parameter P with covariate value equal to 0 and h 2 represents is the estimated Paediatric model of cidofovir population pharmacokinetics JAC influential factor in the pharmacokinetics parameter with covariate value equal to 1. The decision to include the covariate in the model was based on a combination of statistical significance, mechanistic plausibility and the clinical relevance of the relationship. 10 
Model evaluation
The performance of the final model was evaluated on both graphical and statistical criteria: objective function value, precision of parameter estimation [relative standard error (RSE) ,30%] and goodness-of-fit plots (population predictions versus the observed cidofovir plasma concentrations, conditional weighted residuals versus population predictions and time, and individual predictions versus cidofovir plasma concentrations). The 95% CI of the parameters was assessed by the bootstrap method; 1000 bootstrap samples were generated by resampling of the original data set. To examine the agreement between the observed data and prediction intervals derived from the simulated data, a prediction-corrected visual predictive check (pcVPC) was performed by simulating 1000 replicates based on the final model.
Concentrations/effect relationships
AUC 0-24 for the first dose was obtained from the estimated individual pharmacokinetics parameters for each patient. In viraemic patients, virological success was defined as a decrease in the viraemia of at least 1 log 10 copies/mL on day 15 after the first cidofovir infusion. For patients with adenovirus and cytomegalovirus co-infections, virological success was defined as a decrease of !1 log 10 copies/mL of both viremias.
A Wilcoxon test was performed on the overall population in order to assess the association between cidofovir AUC 0-24 and virological success. A Fisher's exact test was then used to test the association between an AUC 0-24 cut-off value and efficacy outcome in the subgroup of adenovirusviraemic children.
Results
Demographic data
Sixteen virological events occurred in 13 patients: eight adenovirus infections/diseases, four cases of asymptomatic adenovirus carriage without viraemia and four cytomegalovirus infections/ diseases. The baseline characteristics of the patients are summarized in Table 1 and Table S1 (available as Supplementary data at JAC Online). All of them suffered from immune deficiencies and all but one had received HSCT. Their median age was 4 years (range 1-12 years). The median body weight was 14 kg (IQR 10-20.3 kg). Overall, 86 results of cidofovir plasma levels were collected for the pharmacokinetics analysis. On average, two occasions per patient were available.
Cidofovir population pharmacokinetics model
A two-compartment model with first-order absorption and elimination adequately described the data. The parameters of this model were: elimination clearance (CL), intercompartmental clearance (Q), and central (V c ) and peripheral (V p ) volumes of distribution.
The residual variability was modelled using a proportional error model. The inter-individual variability of Q and V p were not retained owing to the poor precision of the estimate. A model including the inter-occasion variability was unstable and the weight-based allometric scaling did not improve the fit [change in objective function value (DOFV) " 0].
For the covariate analysis, a power function best described the correlation between CL and CL CR . The exponent for the effect of CL CR on CL was estimated at 0.133 with poor precision and was not statistically significant (DOFV " 0). Covariate analysis showed that V c could be influenced by body weight (DOFV " #5, with a reduction of 23% in inter-individual variability of V c ). This relationship was modelled by a power function; the exponent for the effect was estimated at 0.88. However, the confidence interval of the estimated influential factor for the body weight was wide and ranged close to zero. Consequently, the simplest model was chosen and none of the covariates were retained. The pharmacokinetics parameter estimates from the final model and their 95% CIs are summarized in Table 2 .
The performance of the final model fits is represented by goodness-of-fit plots in Figure 1 . Figure 1(a and b) show agreement between observed and model-predicted plasma cidofovir concentrations. Conditional weighted residual concentrations versus population-predicted concentrations (Figure 1c ) and conditional weighted residuals concentrations versus time (Figure 1d ) showed acceptable model performance: 97.6% of the values were within +2 SD. 11, 12 The pcVPCs showed good overlap of the observed data and prediction concentration profiles ( Figure 2 ). 13 
Virological follow-up
Among eight children with adenovirus viraemia, six (75.0%) reached virological success on day 15 ( Figures S3-S5 , S7, S8, S11-S13). The median duration to obtain undetectable viraemia was 11.3 days (range 5-30 days). None of these children had late viral rebound. Of the two patients (patients #8 and #12) with adenovirus viraemia and initial virological failure, one child (patient #8) reached late undetectable viraemia and the remaining one (patient #12) remained viraemic under the treatment. Four children had asymptomatic stool and/or nasopharyngeal adenovirus carriage without viraemia at the time of cidofovir initiation. None of them developed adenovirus viraemia during cidofovir treatment. All four of these children cleared viral carriage within the month following the first cidofovir infusion ( Figures S2, S6 , S9, S10).
Four children had cytomegalovirus viraemia at the time of cidofovir initiation (Figures S1, S2, S7 and S13). Two of them had concomitant adenovirus viraemia and a third presented with concomitant adenovirus asymptomatic stool carriage. Among children with cytomegalovirus viraemia, one (25%) reached virological success (patient #2). In this patient, undetectable viraemia was obtained during cidofovir treatment. Among the three cytomegalovirus-viraemic patients with virological failure, one (33.3%) reached late viraemia suppression on cidofovir treatment (patient #13).
Two children had concomitant (patient #7) or consecutive (patient #13) cytomegalovirus and adenovirus viraemia. Both of them reached virological success for the adenovirus infection but cidofovir failed to control the cytomegalovirus viraemia. The third co-infected child (patient #2) successfully controlled cytomegalovirus viraemia and cleared adenovirus stool carriage on cidofovir.
Association between drug concentrations and viral replication
In patients with adenovirus and/or cytomegalovirus viraemia at the time of cidofovir initiation, the median AUC 0-24 was 21 mgÁh/L (range 7-73 mgÁh/L). Patients with virological success displayed a Neant et al. 
Evolution of immune deficiency during cidofovir treatment
Eight out of 13 children (61.5%) had an increase in T cell count during cidofovir treatment. Among the 10 cytomegalovirus and/or adenovirus-viraemic patients, the lymphocyte count increased during cidofovir treatment in 7 (70%) children, including 5 patients with virological success. Among the three remaining children with a stable lymphocyte count during cidofovir treatment, two reached virological success.
Safety of cidofovir
No increase in creatininaemia was observed during or after the cidofovir treatment (Table S1 ). Three children previously had a tubulopathy, which did not worsen during cidofovir treatment. One patient with low cidofovir AUC 0-24 levels (18.8 mgÁh/L) developed a tubulopathy after two cidofovir infusions (patient #13). We did not observe cidofovir-related haematotoxicity.
Discussion
As far as we are aware, this study is the first retrospective population pharmacokinetics study of cidofovir in children with data obtained in routine clinical practice. Few published data describe cidofovir pharmacokinetics in paediatric patients. 6 Because cidofovir is often prescribed as a first-line agent for adenovirus infections and as a second-line agent for cytomegalovirus infections in paediatric recipients of HSCT, a better knowledge of cidofovir pharmacokinetics is required. The most adequate model was a two-compartment model as reported in the literature. 6 Estimated typical values for pharmacokinetics parameters in the final model In the case of concomitant (children #2 and #7) or successive (child #13) cytomegalovirus and adenovirus infections in the same child, the characteristics and the evolution of each viral infection are shown in a separate row. Neant et al.
3 L/h and inter-individual variability of CL and V c were 45% and 51% respectively. Pharmacokinetics parameters were estimated with good precision (RSE , 30%). The estimated cidofovir t1 =2 of 2 h was shorter than the previously described value (5.9 h) in children using standard approaches (two-stage methods with a twocompartment model). 6 However, the estimated cidofovir terminal t1 =2 of 2 h (95% CI 1.7-2.3 h) was most similar to the value reported in a pharmacokinetic study in adults (mean + SD 2.3+0.5 h). 4, 5 The allometric model, with fixed power exponents of 1 and 0.75 for volume and CL terms, respectively, is often used in population pharmacokinetics studies in paediatrics but in our model it did not improve the results. 9 The effect of body weight on V c was the only significant covariate; a higher bodyweight was associated with a higher V c . However, the effect size was judged to be not clinically relevant thus this covariate was not retained in the final model. In a previous paediatric study, no effect of covariates was found. 6 However, the influence of probenecid administration on cidofovir pharmacokinetics has been described in a pharmacokinetics study in an adult population. Indeed, a high dose of probenecid was significantly associated with both a lower CL and volume at steady-state. 4 Owing to sparse data, the covariate analysis carried out was limited. It was difficult to fully explain the variability of cidofovir pharmacokinetics. Consequently, we cannot reach conclusions on the effect of weight on the pharmacokinetics parameters. In this study, it was not possible to define dose recommendations.
In our study, the median AUC 0-24 observed for the first dose was 21 mgÁh/L (range 7-73 mgÁh/L). For adenovirus infection, all children with virological success had an AUC 0-24 threshold above 19.1 mgÁh/L, Paediatric model of cidofovir population pharmacokinetics JAC consequently this value was chosen to be associated with efficacy. This result must be interpreted carefully because (i) our analysis was performed with the data obtained from a limited number of patients; and (ii) most of the adenovirus-viraemic patients with virological success had a concomitant increase in their lymphocyte counts, which could contribute to control of the viral infection. Conventional pharmacokinetics measurements do not accurately reflect the duration of action of cidofovir since the antiviral effect is dependent on the intracellular concentrations of the active phosphorylated metabolites within cells. As noted above, these metabolites (whose intracellular concentrations were not evaluated in our study) have a long intracellular t1 =2 (48 h for the HPMPCp-choline adduct 14 ) which may contribute to the prolonged antiviral action of cidofovir. 15 We herein described two cases of late viral suppression in patients (one adenovirus-and one cytomegalovirus-viraemic child) with initial virological failure at day 15. We could thus discuss the relevance of the criteria defining virological success during cidofovir treatment. We used here the criteria used by Ganapthi et al. and other studies [16] [17] [18] (viraemia decrease of at least 1 log 10 copies/mL at day 15). However, we cannot exclude that this strict criterion may underestimate the rate of cidofovir-related virological success, especially in cases with high initial viraemia and profound underlying immune deficiency. Indeed, owing to underlying immunosuppression and corticosteroid use, a modest quantitative increase in viral loads (or antigenaemia) during the first 2 weeks of antiviral therapy may occur in some patients, as previously suggested in the case of some cytomegalovirus-infected HSCT recipients receiving ganciclovir preemptive treatment. 19, 20 Thus, we suggest that, in HSCT recipients with profound immune deficiencies and adenovirus and/or cytomegalovirus infections, less strict cutoff values may be used to define refractory infections, in order not to underestimate the rate of virological success.
In three non-viraemic patients with isolated adenovirus stool carriage after HSCT, cidofovir was initiated in order to prevent adenovirus disease. None of these children developed adenovirus viraemia during cidofovir treatment. These results are in line with the suggestion by Lion et al. 21, 22 that systematic screening of adenovirus intestinal excretion should be part of routine testing during the post-HSCT period in children, in order to discuss antiviral treatment in patients with high adenovirus carriage with the aim of preventing invasive infection. However, this indication is controversial because the presence of adenovirus in stool specimens is a very common finding during the post-transplant period and most of these patients remain asymptomatic and clear the virus without the use of antiviral treatment. 23 Current recommendations for adenovirus screening and monitoring as a basis for preemptive treatment in patients at high risk for adenovirus disease are still relatively diverse and further studies are needed to provide reliable data permitting the establishment of standardized approaches.
Some factors may disturb the interpretation of the correlation between pharmacokinetics and virological follow-up. These include antiviral and immune-suppressive co-medications and concurrent immune reconstitution. In two patients, virological success was observed without concomitant change of the absolute lymphocyte count (Supplementary data). These data contrast with some other studies concluding that cidofovir alone is unable to mediate complete resolution of adenovirus viraemia in the absence of immune recovery. 24 Toxicity is the major concern in the utilization of cidofovir. In this study, no increase in creatinaemia was observed in patients. Moreover, only one of them developed cidofovir-induced tubulopathy. These results are in line with the review published by Ganapathi et al., in which no significant nephrotoxicity (defined by an elevation of 50% of the baseline creatininaemia) was described in 9/14 paediatric studies. In the remaining five paediatric studies, in which nephrotoxicity was observed in 9% to 43% of patients, the duration of cidofovir treatment was much longer than in our patients. 17 There is no approved antiviral agent for the treatment of adenovirus infection. Brincidofovir may be a promising antiviral drug and has in vitro and in vivo activity against adenovirus. Neant et al.
Infusion of donor memory T lymphocytes directed specifically against immunodominant viral antigens is one of the therapeutic options in cytomegalovirus and adenovirus infections. Recent studies showed that rapidly prepared cytomegalovirus-and/or adenovirus-specific T cells seem efficient in a subset of HSCT recipients with severe infections, as one-third of the patients showed a complete virological response in parallel with specific T cell expansion even in the presence of significant corticotherapy. However, the safety of this approach was not adequately assessed and larger studies are needed to assess the clinical and biological parameters associated with virological failure and success. 25 
Conclusions
Cidofovir appears safe and reasonably tolerated for the treatment of adenovirus and cytomegalovirus infections in paediatric allogeneic HSCT and seemed to have antiviral efficacy in a subset of patients. There is no current recommendation for pharmacokinetics surveillance in cidofovir treatment, but our retrospective study suggests that (i) therapeutic drug monitoring of cidofovir may be recommended in children; and (ii) in the case of adenovirus infection, targeting an AUC 0-24 above 19 mgÁh/L is associated with higher probability of virological success. Larger prospective studies are needed to confirm the correlation between cidofovir AUC 0-24 and cidofovir virological efficacy.
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